Belgium (BE)

The EANM guideline for radiosynoviorthesis (2021) Kampen WU, Boddenberg-Paetzold B, Fischer M, Gabriel M, Klett R, Konijnenberg M, Kresnik E, et al. Journal article A Survey on Mixed-Integer Programming Techniques in Bilevel Optimization (2021) Kleinert T, Labbe M, Ljubic I, Schmidt M Journal article Physicians' Opinion and Practice With the Continuous Use of Sedatives in the Last Days of Life (2021) Heijltjes MT, Morita T, Mori M, Heckel M, Klein C, Stiel S, Miccinesi G, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America (2021) Kolarova T, Mcdonnell M, Bouvier CV, Pavel ME, Singh H, Howe J, Singh S, et al. Conference contribution Accessing Photoredox Transformations with an Iron(III) Photosensitizer and Green Light (2021) Aydogan A, Bangle RE, Cadranel A, Turlington MD, Conroy DT, Cauët E, Singleton ML, et al. Journal article Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location (2021) Mahfoud F, Bertog S, Lauder L, Bohm M, Schmid A, Wojakowski W, Parise H, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum